Equities Analysts Issue Forecasts for Globus Medical, Inc.’s FY2026 Earnings (NYSE:GMED)

Globus Medical, Inc. (NYSE:GMED) – Research analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for Globus Medical in a research report issued on Monday, May 6th. Zacks Research analyst R. Department now expects that the medical device company will post earnings per share of $3.77 for the year, up from their prior forecast of $3.76. The consensus estimate for Globus Medical’s current full-year earnings is $2.69 per share.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Tuesday, May 7th. The medical device company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.17. The firm had revenue of $606.67 million for the quarter, compared to analysts’ expectations of $586.82 million. Globus Medical had a net margin of 7.83% and a return on equity of 8.82%. The business’s revenue for the quarter was up 119.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.53 earnings per share.

Several other research firms also recently commented on GMED. Piper Sandler raised their price objective on Globus Medical from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Wednesday. Barclays lifted their price objective on Globus Medical from $83.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a report on Wednesday. Truist Financial boosted their price target on shares of Globus Medical from $58.00 to $60.00 and gave the company a “hold” rating in a report on Wednesday, February 21st. Finally, BTIG Research lifted their price objective on shares of Globus Medical from $60.00 to $63.00 and gave the company a “buy” rating in a report on Wednesday. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Globus Medical currently has an average rating of “Moderate Buy” and a consensus price target of $66.50.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $64.40 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.72 and a current ratio of 4.88. The firm has a market cap of $8.72 billion, a PE ratio of 55.04, a price-to-earnings-growth ratio of 1.53 and a beta of 1.11. The firm’s 50 day simple moving average is $52.71 and its 200-day simple moving average is $51.35. Globus Medical has a one year low of $43.38 and a one year high of $65.74.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale acquired a new stake in shares of Globus Medical during the third quarter worth $28,000. YHB Investment Advisors Inc. purchased a new stake in shares of Globus Medical in the 1st quarter valued at $50,000. Allworth Financial LP increased its stake in shares of Globus Medical by 25.7% in the fourth quarter. Allworth Financial LP now owns 1,242 shares of the medical device company’s stock worth $66,000 after acquiring an additional 254 shares during the period. Mather Group LLC. acquired a new stake in shares of Globus Medical in the first quarter worth $69,000. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Globus Medical by 122.8% during the third quarter. Nisa Investment Advisors LLC now owns 1,493 shares of the medical device company’s stock worth $74,000 after purchasing an additional 823 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Globus Medical

In other news, Director Leslie V. Norwalk sold 10,590 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $51.99, for a total transaction of $550,574.10. Following the completion of the sale, the director now owns 17,419 shares in the company, valued at approximately $905,613.81. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 24.30% of the stock is owned by insiders.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.